Nervonik Closes $52.5m Series B Funding to Advance PNS System

Why It Matters

The infusion of capital positions Nervonik to bring a more precise, data‑driven neuromodulation therapy to a chronic‑pain market that is rapidly expanding, potentially reshaping standards of care.

Key Takeaways

• Nervonik raised $52.5M Series B led by Amzak Health.
• Funding targets advanced sensing and commercial rollout of PNS platform.
• Platform records evoked compound action potentials for personalized therapy.
• Investors include Elevage, USVP, Lumira, Foothill, Shangbay Capital.
• PNS market poised for rapid adoption in chronic pain treatment.

Pulse Analysis

Peripheral nerve stimulation (PNS) has emerged as a compelling alternative to opioid‑based pain management, offering targeted electrical modulation of peripheral nerves to alleviate chronic discomfort. While traditional PNS devices deliver fixed‑pattern stimulation, the next wave of innovation focuses on integrating real‑time feedback to tailor therapy to each patient’s neurophysiology. This shift toward closed‑loop systems promises higher efficacy, reduced side effects, and broader applicability across neurological disorders, positioning the technology at the forefront of the $8‑10 billion neuromodulation market.

Nervonik’s $52.5 million Series B injection, led by Amzak Health and supported by a roster of specialty investors, provides the runway to transition its platform from early‑stage validation to full‑scale commercialization. The round will fund expanded clinical trials, regulatory submissions, and the scaling of its proprietary sensing algorithms that capture evoked compound action potentials. By marrying stimulation with continuous biomarker monitoring, Nervonik aims to deliver a truly personalized therapy—an approach that resonates with investors seeking differentiated, data‑rich medical technologies.

If successful, Nervonik’s intelligent PNS system could accelerate adoption among pain specialists and neurologists, challenging incumbents that rely on open‑loop devices. The company’s ability to demonstrate measurable clinical outcomes will be critical for securing reimbursement and achieving market penetration. Moreover, the involvement of venture firms with deep ties to med‑tech and digital health signals confidence that the platform can navigate regulatory pathways and scale manufacturing. As chronic pain prevalence rises and payers demand value‑based solutions, Nervonik’s funding milestone underscores a broader industry trend toward smarter, patient‑centric neuromodulation therapies.